Advertisement
RDHL ข่าวฟอเร็กซ์
RedHill Says Its Oral Antivirals, Opaganib And RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Specialty biopharmaceutical company RedHill Biopharma Ltd. (RDHL) announced Monday the study results showing in vitro efficacy against the currently dominant Omicron COVID-19 sub-variant BA.5, by both of RedHill's novel, oral, host-directed and broad-acting investigational antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib.
RTTNews
|
938 วันที่ผ่านมา
